Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study

Title
Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study
Authors
Keywords
B cells, Fatigue, Chronic fatigue syndrome, Patients, Mental health and psychiatry, Autoimmune diseases, Polymerase chain reaction, Psoriasis
Journal
PLoS One
Volume 6, Issue 10, Pages e26358
Publisher
Public Library of Science (PLoS)
Online
2011-10-20
DOI
10.1371/journal.pone.0026358

Ask authors/readers for more resources

Reprint

Contact the author

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started